The TACSI study compared the effectiveness of combined treatment of ticagrelor and aspirin with treatment of aspirin alone in patients after heart surgery (bypass) for acute coronary syndrome[1]. They enrolled 2,201 patients (mean age 66 years, 14.4% women) in 22 Nordic cardiovascular centers who received treatment for one year in a randomized clinical trial[1]. The primary objective was to monitor the occurrence of death, myocardial infarction, stroke or the need for repeated revascularization[1]. The results showed that primary adverse events occurred in 4.8% of patients in the ticagrelor plus aspirin group and in 4.6% in the aspirin alone group, not a statistically significant difference[1]. However, the combination treatment caused more major bleeding – 5% compared to 2% in the aspirin group[4]. The study concluded that adding ticagrelor to aspirin did not reduce the risk of adverse cardiovascular events compared to aspirin alone[1]. Based on these findings, aspirin alone remains a safer standard drug after coronary surgery[7].